Incannex Healthcare Limited (IXHL)
$2.90-6.45%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $35M
- Beta
- 2.82
- P/E (TTM)
- -2.83
- Short % float
- 4.62%
- Days to cover
- 3.9
- SI change
- -36.3%
- 1W
- -9.66%
- 1M
- -11.04%
- vs SPY 1W
- -10.08%
- vs SPY 1M
- -13.10%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 13
- GROWTH
- 51
- GARP
- 4
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC-16.5%
REV YoY-
ROE-19.0%
EPS YoY-
ROA-26.4%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-2.83
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B0.58
P/FCF-
EV/EBITDA1.30
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.14
ALTMAN Z-
CURR RATIO48.81
ND/EBITDA-
BETA2.82
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on IXHL?
- LOPJLB’s latest quantitative signal on Incannex Healthcare Limited (IXHL) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IXHL in?
- Incannex Healthcare Limited (IXHL) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Incannex Healthcare Limited (IXHL) do?
- Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obs…